Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
DRKS00010275Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in type 2 diabetes mellitus (T2DM) and obesity (12 cohorts), sponsored by AstraZeneca. Primary endpoints: Efficacy of MEDI0382, Safety of MEDI0382 and 1 more. Started Apr 2016; status: recruiting.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on DRKS00010275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010275.